EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused...

DelveInsight s Clostridium Difficile Infections Market Insights Epidemiology and Market Forecast 2034 report offers an in depth understanding of the Clostridium Difficile Infections historical and forecasted epidemiology as well as the Clostridium Difficile Infections market trends in the United States ...

A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C …

Lumen Bioscience's LMN-201 combines phage-derived endolysin with antibodies to accelerate C. diff cell death and prevent toxin-mediated damage.

Our report demonstrates for the first time the potential of Cwp2_A as an effective vaccine candidate against CDI in mice.

Pharmaceutical Innovations, Collaborative Research Initiatives, and Increased Awareness Driving Clostridium Difficile Infection Treatment Market Growth...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today annou

Las Vegas Nevada United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ...

Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals.

Clostridium Difficile Infections companies working in market are Pfizer, Valneva, GlaxoSmithKline, Summit Therapeutics, MGB Biopharma, Acurx Pharmaceuticals.

spaniClostridioides difficile/i spores are essential for initiation, recurrence and transmission of the disease. The spore surface layers are composed of an outermost exosporium layer that surrounds another proteinaceous layer, the spore coat. These spore surfaces layers are responsible for initial/span …

Donor-derived fecal microbiota treatments are efficacious in preventing recurrent Clostridioides difficile infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen transfer. In contrast, VE303 is a defined consortium of eight puri …

Diarrhea associated with enteric infections, gut inflammation, and genetic defects poses a major health burden and results in significant morbidity and mortality. Impaired fluid and electrolyte absorption and/or secretion in the intestine are the hallmark of diarrhea. Electroneutral NaCl absorption …

Clostridioides difficile is the leading cause of healthcare- and antibiotic-associated diarrhea. Surface layer protein A (SlpA), an essential component of the bacterium's outermost layer, contributes to colonization and inflammation. The peroxisome proliferator-activated receptor gamma (PPAR-γ) has …

Clostridioides difficile (C. difficile) infection (CDI) is a life-threatening healthcare-associated infection occurring worldwide. C. difficile toxins (toxin A and toxin B) are the major virulence factors, causing CDI-related diarrhea and complications. Recent studies have shown that sulfated glycos …

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce weight loss, but LPOXY Therapeutics has penned a

Background: Clostridioides difficile (C. difficile) infection (CDI) is the primary cause of antibioticassociated diarrhea. Due to its high resistance rate to...

/PRNewswire/ -- LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious disease...

Nature Medicine - Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent Clostridioides difficile infection in the context of a...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.

Joseph Zackular, PhD suggests that mRNA vaccines and monoclonal antibodies could offer more effective treatments for recurrent C difficile infections

Pfizer Pflash: A Spotlight on Clostridioides difficile Vaccine Development Presentation intended for 1 ...

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

Joseph Zackular, PhD, shares insights on his team’s mRNA vaccine research for C difficile, highlighting progress in animal models and future plans for human trials.

Clostridioides difficile is a major cause of nosocomial infections, often associated with individuals who have gut dysbiosis from previous antibiotic therapies. C. difficile infections (CDI) have a high recurrence rate and impose significant financial and mortality burdens on the healthcare system. …

Based on our findings, we elucidate a novel mechanism by which PAMK alleviates DSS-induced colitis and thus provides evidence to support the potential development of PAMK as a new clinical drug against UC.

To investigate whether the polysaccharide component of the Traditional Chinese Medicine (TCM) formula Lizhong decoction (LZD) has therapeutic effects and regulates gut microbiota in antibiotic-associated diarrhea (AAD) related to Clostridium difficile infection, a polysaccharide was extracted from L …

Acurx Pharmaceuticals (ACXP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 10. Analyst Ed...

Acurx prepares for Phase 3 trials in C. difficile treatment